Stay updated on Venetoclax and Lintuzumab-Ac225 in AML Patients Clinical Trial
Sign up to get notified when there's something new on the Venetoclax and Lintuzumab-Ac225 in AML Patients Clinical Trial page.

Latest updates to the Venetoclax and Lintuzumab-Ac225 in AML Patients Clinical Trial page
- Check6 days agoChange DetectedThe page’s revision label in the footer updated from v3.5.3 to v3.5.4, indicating a minor update to the record history.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe Record History shows a new revision, v3.5.3, replacing the previous v3.5.2, signaling an update to the record history. This indicates an update to the record history rather than a change to the study content.SummaryDifference0.1%

- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedRevision v3.5.2 was added to the history and revision v3.5.0 was removed.SummaryDifference0.1%

- Check56 days agoChange DetectedAdded Revision: v3.5.0 to the history and removed Revision: v3.4.3.SummaryDifference0.1%

- Check70 days agoChange DetectedNew revision entry v3.4.3 is added and v3.4.2 is removed from the study record history.SummaryDifference0.1%

- Check99 days agoChange DetectedRevision: v3.4.2 was added to the history. Notices about government funding and operating status were removed.SummaryDifference0.8%

Stay in the know with updates to Venetoclax and Lintuzumab-Ac225 in AML Patients Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Venetoclax and Lintuzumab-Ac225 in AML Patients Clinical Trial page.